By
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
When LSN decided to bring RESI to San Diego, we took note of the rhythm of other events and receptions that take place during BIO week. What did we see? A distinct lull on Monday. That's the day when we kick off the week, and LSN saw an opportunity to fill that gap with partnering meetings and early stage focused content.
Adding a day full of meetings prior to BIO is sure to make your week more productive, more connected and more fruitful. And to keep you busy between meetings, RESI has 3 tracks of investor panels and early stage workshops to edify and advise you in your fundraising. If you'd like to join us there, it's not too late -
you can sign up now.
How do you get the most out of a day of networking and one-to-one meetings? It's all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI's uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?
Genomic innovation cuts across many technology verticals. The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.
At RESI, a panel of investors with a focus on genomics will discuss what kind of breakthroughs they are looking to back, and what challenges still remain in the genomics field.
Moderated by
Amanda Cashin (Head of Illumina Accelerator), the participants are:
Beth Hill (Johnson & Johnson Innovation - JLABS)
Jonathan Kabakoff (Alexandria Venture Investments)
Life Science Investor Mandates
When LSN decided to bring RESI to San Diego, we took note of the rhythm of other events and receptions that take place during BIO week. What did we see? A distinct lull on Monday. That's the day when we kick off the week, and LSN saw an opportunity to fill that gap with partnering meetings and early stage focused content.
How do you get the most out of a day of networking and one-to-one meetings? It's all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI's uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?
Genomic innovation cuts across many technology verticals. The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.
